Genmab A/S (OTCMKTS:GNMSF – Get Free Report) was the recipient of a large growth in short interest in August. As of August 31st, there was short interest totalling 11,800 shares, a growth of 6.3% from the August 15th total of 11,100 shares. Based on an average daily trading volume, of 800 shares, the short-interest ratio is presently 14.8 days.
Genmab A/S Stock Performance
GNMSF traded down $4.20 on Tuesday, reaching $372.00. The company had a trading volume of 559 shares, compared to its average volume of 550. Genmab A/S has a one year low of $303.41 and a one year high of $470.50. The company has a fifty day moving average of $383.70 and a 200-day moving average of $387.02.
Genmab A/S (OTCMKTS:GNMSF – Get Free Report) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $3.01 EPS for the quarter. Genmab A/S had a return on equity of 16.93% and a net margin of 28.78%. The company had revenue of $613.43 million for the quarter.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
- Five stocks we like better than Genmab A/S
- What Are Dividend Champions? How to Invest in the Champions
- Hold-It-Forever AutoZone Pulls into Buy Zone
- How to Invest in Renewable Energy
- Virtual Riches: 3 Stocks Leading the VR Revolution
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 5 eCommerce Companies that need to be on Your Watch List
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.